Plasma-derived product · developed by Kamada
Kamada-API is an alpha-1 proteinase inhibitor preparation containing alpha-1 antitrypsin (AAT), a protein purified from human plasma. It is studied in alpha-1 antitrypsin deficiency, a condition in which patients lack sufficient functional AAT.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT00460096 | Phase 2/3 | Alpha 1-Antitrypsin Deficiency | Completed | KMDA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Alpha 1-Antitrypsin Deficiency
See KMDA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KMDA catalysts and pipeline →